Suppliers / Procter & Gamble

Procter & Gamble

United States 2 duplicate records merged Updated 9 July 2026

Procter & Gamble is a finished-dose manufacturer based in United States. It appears in 432 regulatory filings across 19 regulators, without an active US DMF or CEP on file. Its filings concentrate with Health Canada, DIGEMAPS (DO) and AIFA (IT). Its GMP standing is certified by ZLG (DE), NAFDAC (NG) and EMA, among 6 authorities. Its most recent recorded inspection, by US FDA, closed on 27 September 2024 as NAI.

0
active US DMFs
0
valid CEPs
12
registered plants 4 with an FDA FEI number
432
filings across 19 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
4 of 4 confirmed
Inspections
6 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 27 September 2024 NAI US FDA
  • 15 March 2023 VAI US FDA
  • 10 March 2023 VAI US FDA
  • 3 June 2022 NAI US FDA
  • 18 February 2022 VAI US FDA
  • 17 November 2017 VAI US FDA
  • 10 March 2017 VAI US FDA
  • 15 August 2016 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
64521 Grob-Gerau, United Arab Emirates Not on file
Lancy, Switzerland Not on file
Mexico D.F., Colombia Not on file
Germany, Germany 3001903296
Hassia, Germany Not on file
Gross-Gerau, Germany Not on file

6 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
Health Canada 125 None
DIGEMAPS (DO) 80 None
AIFA (IT) 56 None
EEC_EAEU 56 None
INHRR (VE) 20 None
AEMPS (ES) 20 None
ZLG (DE) None 4
NAFDAC (NG) None 3
EMA None 2
US FDA None 1
ANVISA (Brazil) None 1
INVIMA (CO) None 1

Comparing suppliers?

Choose your molecules and target markets. Procter & Gamble comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 27 September 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates